Antibody Therapeutics Xchange West Coast 2019

Target Selection

Titles and Bullets
8:00am – 8:30am


8:30am – 9:00am

Opening Address & Keynote: Ongoing Challenges Faced by the Antibody Sector – Seema Kantak, Executive Director, Biotherapeutics, Exelixis 

9:05am – 10:05am

Single agent vs. combinations; antibody or other platform (fragments, bispecific, etc)
  • What is the situation?  
  • Swiss Army Knife Approach: piling multiple non-dependent targets on a single molecule
  • MoA completely depends on BiS
  • MoA may be enhanced by BiS
  • Early regulatory and CMC advantages may come back to bite you in later stages
  • Is there a future regulatory path for recombinant polyclonal therapeutics?

Vice President Antibody Therapeutics
Gritstone Oncology

Portrait picture of Jonah Rainey
10:10am – 10:40am

1-2-1 Meetings / Networking Break

10:40am – 10:50am

Morning Refreshments

10:50am – 11:50am

Implementing discovery strategies to value the therapeutic potential of lead antibody candidates
  • Optimal discovery method versus available budget – how do we decide the best path?
  • Animal immunizations, natural human antibody repertoire library selection, or synthetic library selection – what are the pros and cons?
  • What is the best strategy for choosing the lead candidate selection criteria and at what point should a functional study be integrated – early or later?
  • What are the ideal immunization and selection tools? If appropriate cell lines and/or recombinant proteins are not available?

Director of Sales
ImmunoPrecise Antibodies

Barry Duplantis received a double major in Biochemistry and in Chemistry, and his Ph.D. in Microbiology from the University of Victoria in 2011, where he specialized in intracellular pathogenesis, bacterial genetics and synthetic biology. He subsequently founded and was CEO of DuVax Vaccines and Reagents Inc, a biotechnology company that specialized in the development of bacterial vaccines. Under Barry, DuVax successfully entered into collaborative research projects with two major pharmaceutical companies and delivered vaccines candidates for two separate pilot studies.  He has also sat on the advisory board of biotechnology companies in the Victoria and Vancouver, B.C. areas.

Portrait picture of Barry DuPlantis
11:55am – 12:25am

1-2-1 Meetings / Networking Break

12:30pm – 1:30pm

Preclinical validation: How much is enough and are animal models useful in every case?
  • What does it mean (to you) to validate a target?
  • What alternative criteria are used to justify discovery on a non-validated target?
  • Can an imperfect animal model stand in the way of a perfectly good drug? 
  • When is a cell-based model superior to an animal model?

Principal Scientist
NGM Biopharmaceuticals

Alan is experienced with pre-clinical biologic drug discovery campaigns for a wide range of targets.  He has served as project leader and engineering lead for both antibody and non-antibody biologic drug candidates. 

Prior to NGM, Alan received his Ph.D. from UC San Diego for investigations of transcriptional regulation, post-doctoral training at UCSF, and then stints with Roche (Palo Alto), and Altravax.

Portrait picture of Alan Kutach
1:30pm – 2:30pm

Networking Lunch

2:30pm – 3:00pm

Poster Session – DeepDisplay™: a ground-breaking and influential human lead antibody discovery platform utilizing OmniAb® animals –
ImmunoPrecise Antibodies

3:00pm – 3:30pm

1-2-1 Meetings / Networking Break

3:30pm – 3:40pm

Afternoon Refreshments

3:40pm – 4:10pm

1-2-1 Meetings / Networking Break

4:15pm – 5:15pm

Prioritisation: so many targets, so little time
  • How do you nominate a potential drug target?
  • How do you rate target tractability?
  • What do you require before committing any resources to investigate a target?
  • How do you deal with competing priorities within you discovery group?
  • How early do you engage other groups in target prioritization (translational, Non-Clinical, Clinicaland business development?

Head of Antibody & Assay Development

Robin has been involved in the development of monoclonal antibodies for over 25 years. At Elan, she headed the group that developed both the murine version of Natalizumab for Multiple Sclerosis and Bapineuzumab for Alzheimer’s Disease.   At Prothena, currently 2 additional antibodies developed by her group are in Clinical Trials, one for the treatment of Parkinson’s Disease in Phase II, and the other for the treatment of TTR amyloidosis in phase I.  Additionally, her group develops all pre-clinical and clinical assays for PK, ADA and biomarkers needed for Prothena’s programs.  

Portrait picture of Robin Barbour
5:15pm – 5:45pm

Closing Keynote & Address: Future Challenges and Opportunities of Antibody-Based Therapeutics – Nathan Trinklein, Chief Technology Officer, TeneoBio


Canape/Drinks Reception


Antibody Therapeutics Xchange | West Coast 2019